Core Insights - Psyence Biomedical Ltd. is the first publicly listed company to investigate the potential impact of psilocybin on longevity, collaborating with researchers in South Africa [1][6] - The initiative aims to explore psilocybin's effects on biological markers associated with aging, which could redefine human longevity and transform aging [1][6] Industry Context - Longevity science is gaining global attention due to aging populations and rising healthcare costs, with public figures like Bryan Johnson promoting psychedelic therapies for longevity [2][6] - Scientific literature supports the intersection of psychedelics and aging biology, with preclinical research indicating that psilocin can extend survival in aged mouse models and increase the lifespan of human cells by over 50% [2] Research Initiative - Psyence BioMed is developing a preclinical protocol to evaluate psilocybin's influence on biological mechanisms related to aging, focusing on biomarkers of cellular stress, inflammation, and mitochondrial function [3] - The research will be led by Dr. Tanya Calvey, a recognized neuroscientist specializing in neuropsychopharmacology, to rigorously investigate the effects of psilocybin on aging [4][5] Strategic Positioning - The initiative complements Psyence BioMed's existing clinical programs, including psilocybin-assisted therapy trials for palliative care patients, advancing the company's mission to explore the therapeutic potential of psilocybin and ibogaine [7] - The company is positioned at the forefront of a new therapeutic arena, with significant interest in understanding how psilocybin may influence biological aging [6]

Industry Focus - Longevity science is being supported by bridging crypto and biotech [1] - HQ Longevity VC is acting as a patron in the fight against aging [1] Company Insight - HQ Longevity VC is transitioning from finance outsiders to longevity science supporters [1]